MARKET

ZYME

ZYME

Zymeworks
NYSE

Real-time Quotes | Nasdaq Last Sale

39.88
-1.44
-3.49%
After Hours: 39.88 0 0.00% 16:54 10/28 EDT
OPEN
40.64
PREV CLOSE
41.32
HIGH
40.64
LOW
39.62
VOLUME
318.42K
TURNOVER
--
52 WEEK HIGH
52.75
52 WEEK LOW
20.33
MARKET CAP
1.82B
P/E (TTM)
-10.5991
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
ImmunoPrecise teams up with Zymeworks for COVID-19 antibody
ImmunoPrecise Antibodies (IPATF) announces a research collaboration with Zymeworks (ZYME) giving the Company access to Zymeworks' Azymetric and EFECT platforms for the further development of its multiple antibody candidates to fight
Seekingalpha · 09/17 12:00
ImmunoPrecise Announces New Multi-Specific SARS-CoV-2 Antibody Collaboration With Zymeworks
https://www.prnewswire.com/news-releases/immunoprecise-announces-new-multi-specific-sars-cov-2-antibody-collaboration-with-zymeworks-301133132.html
Benzinga · 09/17 11:41
Hedge Funds Can’t Stop Buying Zymeworks Inc. (ZYME)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
Insider Monkey · 09/15 04:49
Zymeworks (ZYME) Presents at Wells Fargo Securities 2020 Virtual Healthcare Conference - Slideshow
The following slide deck was published by Zymeworks Inc. in conjunction with this event.
Seekingalpha · 09/11 21:40
Checkpoint Therapeutics, Nano-X Imaging leads healthcare gainers, Evofem Biosciences, Satsuma Pharmaceuticals among major losers
Gainers: Checkpoint Therapeutics (CKPT) +29%, Nano-X Imaging (NNOX) +21%, Biofrontera AG (BFRA) +20%, Zymeworks (ZYME) +14%, MEI Pharma (MEIP) +12%.Losers: Evofem Biosciences (EVFM) -20%, Satsuma Pharmaceuticals (STSA) -11%, Corbus Pharmaceuticals Holdings (CRBP) -10%, Savara (SVRA) -9%, BiondVax Pharmaceuticals (BVXV) -8%.
Seekingalpha · 09/11 15:05
Zymeworks to Present at Upcoming Investor Conferences
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in three upcoming virtual investor conferences.
Business Wire · 09/03 12:30
CRM, HPE, LRN and GOSS among after-hours movers
Gainers: [[CRM]] +12.9%. [[URBN]] +12.3%. [[HPE]] +7%. [[INTU]] +5.6%. [[BWAY]] +5.1%.Losers: [[PSTG]] -7.7%. [[LRN]] -5.9%. [[JWN]] -5.5%. [[GOSS]] -4.9%. [[ZYME]] -4.5%.
Seekingalpha · 08/25 21:46
Is a Surprise Coming for Zymeworks (ZYME) This Earnings Season?
Zymeworks (ZYME) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks · 08/06 12:43
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZYME. Analyze the recent business situations of Zymeworks through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ZYME stock price target is 54.43 with a high estimate of 70.00 and a low estimate of 42.00.
EPS
Institutional Holdings
Institutions: 169
Institutional Holdings: 36.93M
% Owned: 80.93%
Shares Outstanding: 45.63M
TypeInstitutionsShares
Increased
46
5.14M
New
61
-1.33M
Decreased
28
2.49M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.24%
Pharmaceuticals & Medical Research
-2.11%
Key Executives
Chairman/Director/
Nick Bedford
President/Chief Executive Officer/Director/
Ali Tehrani
Chief Financial Officer/Primary Contact/
Neil Klompas
Chief Technology Officer/
Surjit Dixit
Other/
Diana Hausman
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ZYME
Zymeworks Inc. a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The Company operates through a number of platforms, including Azymetric, which is a bispecific platform enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets; ZymeLink, which is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins, and EFECT, which enables finely tuned modulation (both up and down) of immune cell recruitment and function. Its lead product candidate is ZW25, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). It also developed ZW49, combines the design of ZW25 with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Zymeworks Inc stock information, including NYSE:ZYME real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZYME stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZYME stock methods without spending real money on the virtual paper trading platform.